| 1 |
34838486 | [Angiogenesis inhibitors: mechanism of action and nephrotoxicity]. | 2022 Feb |
1 |
| 2 |
35016637 | Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. | 2022 Jan 11 |
1 |
| 3 |
35234063 | Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway. | 2022 Jan-Dec |
2 |
| 4 |
35245519 | Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk. | 2022 May 15 |
3 |
| 5 |
33402115 | Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study. | 2021 Jan 5 |
2 |
| 6 |
33485105 | Biphenylurea/thiourea derivatives tagged with heteroarylsulfonamide motifs as novel VEGFR2 inhibitors; Design, synthesis and anti-angiogenic activity. | 2021 Feb |
1 |
| 7 |
33640712 | Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo. | 2021 Apr |
1 |
| 8 |
33860837 | Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma. | 2021 Jul |
2 |
| 9 |
33948974 | Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review. | 2021 Jul |
1 |
| 10 |
34089726 | Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2. | 2021 Sep 1 |
1 |
| 11 |
34104226 | Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. | 2021 |
1 |
| 12 |
34434234 | Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT. | 2021 |
2 |
| 13 |
32521890 | Sorafenib combined with transarterial chemoembolization prolongs survival of patients with advanced hepatocellular carcinoma. | 2020 Mar-Apr |
1 |
| 14 |
33080958 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. | 2020 Oct 18 |
1 |
| 15 |
33195657 | Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report. | 2020 Oct 26 |
1 |
| 16 |
30352941 | A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma. | 2019 Feb |
4 |
| 17 |
30385613 | Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. | 2019 Jan 1 |
3 |
| 18 |
30543051 | Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. | 2019 Aug |
1 |
| 19 |
30569112 | Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma. | 2019 Mar |
6 |
| 20 |
30600478 | Goals and targets for personalized therapy for HCC. | 2019 Mar |
1 |
| 21 |
30722031 | Overview of current and future systemic therapy for metastatic renal cell carcinoma. | 2019 May 1 |
1 |
| 22 |
30935424 | Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. | 2019 Apr 1 |
1 |
| 23 |
30962952 | The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. | 2019 |
1 |
| 24 |
31195212 | Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. | 2019 Jul |
1 |
| 25 |
31391334 | Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. | 2019 Aug 8 |
1 |
| 26 |
31471309 | Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. | 2019 Oct 15 |
1 |
| 27 |
31497714 | PluS Nanoparticles Loaded with Sorafenib: Synthetic Approach and Their Effects on Endothelial Cells. | 2019 Aug 27 |
1 |
| 28 |
31646819 | Analysis of efficacy of sorafenib combined with vascular endothelial growth factor inhibitor on renal cell carcinoma. | 2019 Jul-Aug |
1 |
| 29 |
29289530 | A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs. | 2018 Jan |
1 |
| 30 |
29426804 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). | 2018 Jun |
1 |
| 31 |
29464101 | Pneumatocele during sorafenib therapy: first report of an unusual complication. | 2018 Jan 19 |
2 |
| 32 |
29514844 | COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment. | 2018 Jul 1 |
1 |
| 33 |
29620259 | Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. | 2018 Jun |
2 |
| 34 |
29703600 | Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. | 2018 Jun |
1 |
| 35 |
29739298 | Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. | 2018 Dec |
1 |
| 36 |
29888133 | Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma. | 2018 |
3 |
| 37 |
30158382 | Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma. | 2018 Sep 26 |
3 |
| 38 |
30202791 | Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. | 2018 |
1 |
| 39 |
30292139 | A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma. | 2018 Dec 7 |
1 |
| 40 |
30369518 | Interleukin-6 induces drug resistance in renal cell carcinoma. | 2018 Dec 8 |
1 |
| 41 |
30378405 | A man in his 50s with neurological symptoms during cancer treatment. | 2018 Oct 30 |
1 |
| 42 |
27981515 | Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. | 2017 Sep |
1 |
| 43 |
28243971 | Erratum to: Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. | 2017 Sep |
1 |
| 44 |
28276433 | Renal cell carcinoma. | 2017 Mar 9 |
2 |
| 45 |
28454454 | Chemotherapy regimen based on sorafenib combined with 5-FU on HIF-1α and VEGF expression and survival in advanced gastric cancer patients. | 2017 Apr |
4 |
| 46 |
28670885 | Anti-Vascular Endothelial Growth Factor Effects of Sorafenib and Arsenic Trioxide in Acute Myeloid Leukemia Cell Lines | 2017 Jun 25 |
2 |
| 47 |
28903416 | Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. | 2017 Aug 15 |
1 |
| 48 |
29190987 | Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. | 2017 Nov 3 |
1 |
| 49 |
29359059 | Sunitinib-Induced Acute Interstitial Nephritis in a Thrombocytopenic Renal Cell Cancer Patient. | 2017 |
2 |
| 50 |
26667599 | Paradoxical exacerbation of chronic plaque psoriasis by sorafenib. | 2016 Jun |
3 |